denkapparat Operations GmbH Invests $390,000 in Halozyme Therapeutics, Inc. $HALO

denkapparat Operations GmbH bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent filing with the SEC. The firm bought 4,988 shares of the biopharmaceutical company’s stock, valued at approximately $390,000.

Several other hedge funds have also recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC increased its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Abel Hall LLC lifted its stake in shares of Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 129 shares during the period. StoneX Group Inc. increased its holdings in Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 132 shares in the last quarter. Twin Capital Management Inc. grew its position in Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the period. Finally, Coldstream Capital Management Inc. lifted its holdings in Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 165 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 32,478 shares of company stock valued at $3,076,604. 2.50% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst maintains Buy rating: HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics, supporting the bullish view of the company’s growth outlook. HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics
• Positive Sentiment: Higher earnings expectations: Zacks Research raised its FY2026 EPS forecast to $8.24 from $7.56, above the provided consensus estimate of $7.98. It also lifted forecasts for several 2027 and 2028 quarters, including FY2027 EPS to $9.01 from $8.96, indicating improving expectations for Halozyme’s earnings trajectory. Zacks Research Issues Positive Forecast for HALO Earnings
• Positive Sentiment: Value and growth appeal: Zacks included HALO among four high-growth stocks with discounted PEG ratios for 2026. The designation may attract investors seeking earnings growth at a relatively reasonable valuation, particularly after Halozyme’s strong recent results and revenue growth. 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
• Neutral Sentiment: Momentum has been strong: HALO recently hit a new one-year high, reflecting investor enthusiasm and continued upward momentum. However, trading near that high can also increase sensitivity to profit-taking and valuation concerns. Halozyme Therapeutics Hits New 1-Year High
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21, a minor reduction that partially offsets the otherwise positive revisions.

Halozyme Therapeutics Stock Performance

HALO stock opened at $110.19 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a 50 day simple moving average of $90.76 and a 200 day simple moving average of $75.82. The stock has a market cap of $12.51 billion, a P/E ratio of 32.89, a P/E/G ratio of 0.43 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HALO. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.